ZNTL vs. ALXO, ETNB, PRAX, OPK, EOLS, TNGX, ARQT, SPRY, ABVX, and PLRX
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include ALX Oncology (ALXO), 89bio (ETNB), Praxis Precision Medicines (PRAX), OPKO Health (OPK), Evolus (EOLS), Tango Therapeutics (TNGX), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical preparations" industry.
ALX Oncology (NASDAQ:ALXO) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.
In the previous week, Zentalis Pharmaceuticals had 17 more articles in the media than ALX Oncology. MarketBeat recorded 30 mentions for Zentalis Pharmaceuticals and 13 mentions for ALX Oncology. Zentalis Pharmaceuticals' average media sentiment score of 0.92 beat ALX Oncology's score of 0.44 indicating that ALX Oncology is being referred to more favorably in the media.
98.0% of ALX Oncology shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by insiders. Comparatively, 6.1% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ALX Oncology's return on equity of -46.05% beat Zentalis Pharmaceuticals' return on equity.
ALX Oncology has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.
ALX Oncology currently has a consensus price target of $18.83, suggesting a potential upside of 25.39%. Zentalis Pharmaceuticals has a consensus price target of $37.14, suggesting a potential upside of 210.04%. Given ALX Oncology's higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than ALX Oncology.
ALX Oncology is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zentalis Pharmaceuticals received 12 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 65.00% of users gave Zentalis Pharmaceuticals an outperform vote while only 61.54% of users gave ALX Oncology an outperform vote.
Summary
Zentalis Pharmaceuticals beats ALX Oncology on 9 of the 15 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
